



A newsletter from Lantern Pharma®

The Spark :: Lantern Pharma Monthly Newsletter

By Lantern Communications Team • Sep 12, 2022


Smart Brevity® count: 3.5 mins...873 words

In the second edition of the Lantern Pharma Newsletter you will find:

- Phase 2 Harmonic™ clinical trial for LP-300 continues momentum with the activation of two cancer center sites and the launch of a patient-focused website
- Lantern Pharma to host KOL webinar Sept. 22nd for Childhood Cancer Awareness Month
- RADR® insights lead to accelerating the development of Actuate Therapeutics drug candidate Elraglusib
- Scientific and investor conferences Lantern will be attending in Q3/Q4

Feel free to send us your feedback by clicking on the **thumb** emoji in the email footer, or by emailing us at newsletter@lanternpharma.com.

Harmonic™ Clinical Trial Updates



1) Lantern has activated its first two Harmonic™ clinical trial sites:

- [Northwest Oncology and Hematology](#) in Rolling Meadows, IL, 60008
- [Gabrail Cancer Center](#) in Canton, OH, 44718
- Both sites are in the process of screening patients and are targeting to enroll the first patients this quarter. Additional sites are expected to be activated in the coming weeks.

2) The Harmonic™ clinical trial website is now live at www.harmonictrial.com.


- The website provides information about the Harmonic™ trial and allows potential patients and their caregivers to see if they qualify for the trial.

3) A unique aspect of the Harmonic™ clinical trial is that liquid biopsies will be collected from patients and analyzed at 4 time points: at enrollment prior to treatment; after the initial 3 treatments; after 6 treatments; and at completion of treatment.

- **Why it matters:** The liquid biopsies will be analyzed for both genomic and transcriptomic data, representing one of the largest and most comprehensive biomarker studies done on the never-smoker NSCLC patient population.
- **The bottom line:** These biopsies will provide key biomarker data for RADR® for a potential pivotal Phase 3 trial and to further understand the response biology of never-smokers with NSCLC.

Lantern Pharma to Host KOL Webinar Sept. 22nd for Childhood Cancer Awareness Month

Lantern Collaboration Partner



UT Health
San Antonio
Greehey Children's Cancer Research Institute

Peter Houghton Ph.D.

Professor & Principal Investigator at Greehey Children's Cancer Research Institute (GCCRI) at UT Health Science Center-San Antonio

On **September 22nd at 12:00pm ET**, Lantern Pharma will be hosting a Key Opinion Leader (KOL) webinar on LP-184, LP-284, and the treatment of pediatric cancers.

The webinar will feature a leading pediatric cancer researcher and Lantern collaborator, Peter Houghton, Ph.D., Professor & Principal Investigator at Greehey Children's Cancer Research Institute (GCCRI) at UT Health Science Center-San Antonio.


Why it matters: [September is Childhood Cancer Awareness Month](#) and was created to drive awareness for pediatric cancer patients and the disparities that exist in pediatric cancer research and drug development:

- In the US, pediatric cancer is the leading cause of death for children between the ages of 4 and 14.
- Every three minutes, a child is diagnosed with cancer, and nearly 300,000 children are diagnosed with cancer each year worldwide.
- To date, there are only 6 drugs that have been developed specifically for children with cancer, and there is an urgent and unmet clinical need for new therapies.
- Lantern's drug candidates LP-184 and LP-284 are in preclinical development for several rare and malignant childhood cancers.

[Click here to register early.](#)

Throughout September, Lantern will be raising awareness for Childhood Cancer Awareness month through [Twitter](#) and [LinkedIn](#) posts.

RADR® Insights Lead to Accelerating the Development of Actuate Therapeutics Drug Candidate Elraglusib



Actuate Therapeutics, Inc. is a private clinical stage biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis.

Lantern entered a collaboration with Actuate Therapeutics, Inc. in Q2 of 2021 to leverage RADR® to accelerate the development of biomarkers for Actuate's drug candidate, elraglusib (also known as 9-ING-41).


Why it matters: Using advanced ML ensemble based algorithms and other computational approaches, RADR® has aided in the identification of actionable biomarkers and modeling patient clinical response to elraglusib. These insights are being used to inform the design of Phase 2 randomized clinical trials for elraglusib.

What's next: These methods will be applied for biomarker validation and will be expanded to incorporate modeling with patient data including, RNA, ctDNA, and soluble biomarkers.

Lantern has received equity in Actuate and has the potential to receive additional equity upon meeting development milestones.


New Preclinical Data on LP-184 and LP-284 will Be Presented at Two Scientific Conferences in Q3

September



AACR Special Conference: Pancreatic Cancer

September 13th -16th , 2022 in Boston, MA



SOHO 2022 Annual Meeting


September 28th – October 1st, 2022 in Houston, TX

Lantern will be presenting new preclinical data at several conferences this quarter:

- The American Association for Cancer Research (AACR) Special Conference: Pancreatic Cancer - September 13-16, 2022 in Boston, MA
[Click here to register.](#)
- The Society of Hematologic Oncology (SOHO) 2022 Annual Meeting - September 28-October 1, 2022 in Houston, TX
[Click here to register.](#)

Additional information about the new preclinical data can be heard at the conference presentations or seen in upcoming press releases.

Lantern Pharma Management to Speak at Multiple Investor Conferences This Fall



Lantern Pharma management will be presenting at:

H.C. Wainwright's 24th Annual Global Investment Conference, September 12-14, 2022 in New York, NY. [Click here to register.](#)

- **Presenter:** Panna Sharma, Lantern's CEO & President, will have an on-demand, virtual presentation that will be available starting at 7:00am ET on Monday September 12, 2022. [Click here to watch.](#)


MicroCap Rodeo Presents: Windy City Roundup, October 12-13, 2022 in Chicago, IL. [Click here to register.](#)

- **Presenter:** Panna Sharma - presentation time TBA

ThinkEquity Conference, October 26, 2022 in New York, NY. [Click here to register.](#)

- **Presenters:** Panna Sharma and David Margrave, Lantern's CFO - presentation time TBA

Watch Panna's Recent Interview on Bloomberg U.S. on the RedChip Money Report



In a recent RedChip Money Report interview, Panna discussed a wide range of topics including:

- How RADR® is helping Lantern and its collaborators to lower the cost of oncology drug discovery and development.
- Lantern's diverse portfolio, which includes 4 drug candidates, an antibody-drug conjugate program and covers 9+ disclosed indications.
- The world-class collaborations that are helping to accelerate the development of Lantern's drug candidates into clinical trials.

The full interview can be viewed [here](#).

Connect With Us on LinkedIn and Twitter

connect with us!

Follow Lantern Pharma on [Twitter](#) and [LinkedIn](#) for all of the latest updates.

Forward-Looking Statements

This newsletter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events,

our plans to advance the development of our drug candidates and antibody drug conjugate program, or our future financial performance. Any statements that are not statements of historical fact (including, without limitation,

statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a

number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR® A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 10, 2022. You may access our Annual Report on Form 10-K for the year ended

December 31, 2021 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this newsletter represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

Feedback


Anonymously tell us what you thought of this newsletter. Your responses will help us create better content for you!

Was this edition useful?



[Click here to unsubscribe.](#)

This newsletter is powered by



Like this email style and format?

It's called Smart Brevity®. Hundreds of orgs use it — in a tool called [Axios HQ](#) — to drive productivity with clearer workplace communications.

This email was sent by Lantern Pharma via [Axios HQ](#)